source
- Mirum receives FDA approval for Atebrioz, third therapy for ultra-rare bone disease FOPMirum Pharmaceuticals announced that the U.S. Food and Drug Administration approved its ALK2 inhibitor, zilurgisertib, to be marketed as Atebrioz, for the treatment of fibrodysplasia ossificans pro…
- Merck signs up to $2.13 billion deal with SciBrunch for preclinical KRAS inhibitor SPR2015Merck announced it has completed a deal with Chinese biotech SciBrunch Therapeutics, paying $400 million upfront for exclusive global rights to develop, manufacture and commercialize SciBrunch’s pr…